الفهرس Only 14 pages are availabe for public view
 |  | from | 115 |  |  |
| | | from | 115 | | |
Abstract
Background: Colorectal cancer (CRC) is the third most common malignant tumor worldwide (Yousefi et al., 2016). Peroxisome proliferator-activated receptor-Þ (PPARÞ) is a member of nuclear receptor superfamily of ligand activated transcription factors, encoded by PPARÞ gene. Pro12Ala polymorphism is a common variant of the PPARÞ2 gene (substitution proline for alanine at codon 12). Many studies discussed the association between PPARÞ2Pro12Ala polymorphism and CRC risk (Wang et al., 2015), but produced controversial results. The heterogenicity of the results in various ethnic populations may be referred to differences in lifestyle, environmental factors, and genetic predisposition (Namvaran et al., 2011; Liang et al., 2017). Objective: To assess the relation between Peroxisome Proliferator-Activated Receptor-Þ (PPARÞ) Pro12Ala polymorphism and CRC susceptibility in Egyptian patients. Methods: Sixty CRC patients and sixty-five apparently healthy subjects were tested for Pro12Ala (rs1801282) genotype by Taqman Real-Time PCR. Results:There was a significant difference in the distribution of PPARÞ2Pro12Ala GC (heterozygous) genotype between CRC patients (11.7%) and healthy control subjects (1.5%) with (p= 0.028 and OR= 8.453; 95% Confidence Interval= 1.008-70.893). According to the alleles CRC cases have a significant higher percentage of G allele (5.8%) than the controls (0.8%) with (p= 0.030 and OR= 7.991; 95% Confidence Interval= 0.968- 65.943). CRC cases with positive family history have a significant increased frequency of GC (heterozygous) genotype (75%) versus (25%) for the negative family history patients with (p= 0.004 and OR= 22.714; 95% Confidence Interval= 2.722-189.516)